The next generation of artificial pancreas control algorithms

Journal of Diabetes Science and Technology

Volumn 2, Issue 1, 2008, Pages 105-112

  Teixeira, Rodrigo E ^a   Malin, Stephen ^a  

^a CFD RESEARCH CORPORATION   (United States)

Author keywords

Artificial pancreas; Control; Diabetes; Glucagon; Meal; Model; Stress

Indexed keywords

EID: 70449480212     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680800200115     Document Type: Review

References (47)

1. Hovorka R, Wilinska M, Chassin L, Dunger D. Roadmap to the artificial pancreas. Diabetes Res Clin Prac. 2006;74:S178-82.
2. Klonoff DC. The artificial pancreas: how sweet engineering will solve bitter problems. J Diabetes Sci Technol. 2007;1:72.
3. Association American Diabetes. Standards of medical care in diabetes. Diabetes Care. 2005;28:S4-36.
4. Davis S, Alonso MD. Hypoglycemia as a barrier to glycemic control. J. Diabetes Complications. 2004;18:60-8.
5. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
6. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulindependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr. 1994;125:117-88.
7. Diabetes Control and Complications Trial Research Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 22). Lancet. 1998;352:837-53.
8. Association American Diabetes. Implications of the Diabetes Control and Complications Trial. Clin Diabetes. 1993;11:91-6.
9. Eastman RC, Siebert CW, Harris M, Gorden P. Clinical Review 51: implications of the Diabetes Control and Complications Trial. J Clin Endocrinol Metab. 2007;77:1105-7.
10. Van Cauter E, Polonsky KS, Scheen AJ. Roles of circadian rhythmicity and sleep in human glucose regulation. Endocr Rev. 1997;18:716-38.
11. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456-69.
12. Piché ME, Arcand-Bossé JF, Després JP, Pérusse L, Lemieux S, Weisnagel SJ. What is a normal glucose value? Differences in indexes of plasma glucose homeostasis in subjects with normal fasting glucose. Diabetes Care. 2004;27:2470-7.
13. Vahl TP, D'Alessio DA. Gut peptides in the treatment of diabetes mellitus. Expert Opin Investig Drugs. 2004;13:177-88.
14. Ludvik B, Thomaseth K, Nolan JJ, Clodi M, Prager R, Pacini G. Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects. Eur J Clin Invest. 2003;33:316-22.
15. Zdrojewicz Z, Belowska-Bien K. Amylin: structure, function, clinical meaning. Diabet Doswiadczalna Klin. 2006;6:169.
16. Gopinath R, Bequette BW, Roy RJ, Kaufman H, Yu C. Issues in the design of a multirate model-based controller for a nonlinear drug infusion system. Biotechnol Prog. 1995;11:318-32.
17. Kwok KY, Shah SL, Clanachan AS, Finegan BA. Evaluation of a long-range adaptive predictive controller for computerized drug delivery systems. Proc. IFAC Adaptive Signals in Control and Signal Processing Conference; 1992. p. 317-22.
18. Wada DR, Ward DS. Open loop control of multiple drug effects in anesthesia. IEEE Trans Biomed Eng. 1995;42:666-77.
19. Hovorka R, Chassin LJ, Wilinska ME, Canonico V, Akwi JA, Federici MO, Massi-Benedetti M, Hutzli I, Zaugg C, Kaufmann H, Both M, Vering T, Schaller HC, Schaupp L, Bodenlenz M, Pieber TR. Closing the loop: the adicol experience. Diabetes Technol Ther. 2004;6:307-18.
20. Thukral A, Galley P, Weinert S, Vering T. Conversion of an empirical closed loop algorithm into the MPC framework. Diabetes Technol Ther. 2004;6:275.
21. Kalatz B, Hoss U, Gessler R, Sternberg F, Lohmann S. Development of algorithms for feedback-controlled subcutaneous insulin infusion with insulin lispro. Acta Diabetol. 1999;36:215.
22. Steil GM, Rebrin K, Janowski R, Darwin C, Saad MF. Modeling beta-cell insulin secretion-implications for closed-loop glucose homeostasis. Diabetes Technol Ther. 2003;5:953-64.
23. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med. 2005;23:1-12.
24. Bergman R. Minimal model: perspective from 2005. Horm Res. 2005;64:8-15.
25. Srinivasan R, Kadish AH, Sridhar R. A mathematical model for the control mechanism of free fatty acid-glucose metabolism in normal humans. Comput Biomed Res. 1970;3:146-65.
26. Tiran J, Galle KR, Porte D Jr. A simulation model of extracellular glucose distribution in the human body. Ann Biomed Eng. 1975;3:34-46.
27. Guyton JR, Foster RO, Soeldner JS, Tan MH, Kahn CB, Koncz L, Gleason RE. A model of glucose-insulin homeostasis in man that incorporates the heterogeneous fast pool theory of pancreatic insulin release. Diabetes. 1978;27:1027-42.
28. Cobelli C, Federspil G, Pacini G, Salvan A, Scandellari C. An integrated mathematical model of the dynamics of blood glucose and its hormonal control. Math Biosci. 1982;58:27-60.
29. Sorensen JT. A physiological model of glucose metabolism in man and its use to design and access improved insulin therapies for diabetes. Chemical Engineering. Massachusetts, MIT; 1985. p. 557.
30. Hedbrant J, Ludvigsson J, Nordenskjold K. Särimner: a computer model of diabetes physiology for education of physicians and patients. Diabetes Res Clin Pract. 1991;14:113.
31. Lehmann ED, Deutsch T. A physiological model of glucose-insulin interaction in type 1 diabetes mellitus. J Biomed Eng. 1992;14:235-42.
32. Dalla Man C, Raimondo DM, Rizza RA, Cobelli C. GIM, simulation software of meal glucose-insulin model. J Diabetes Sci Technol. 2007;1:323.
33. Björntorp P, Holm G, Rosmond R. Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus. Diabet Med. 1999;16:373-83.
34. Chan O, Inouye K, Riddell MC, Vranic M, Matthews SG. Diabetes and the hypothalamo-pituitary-adrenal (HPA) axis. Minerva Endocrinol. 2003;28:87-102.
35. Dempsher DP, Gann DS, Phair RD. A mechanistic model of ACTH-stimulated cortisol secretion. Am J Physiol Regul Integr Comp Physiol. 1984;246:R587-96.
36. Brown EN, Meehan PM, Dempster AP. A stochastic differential equation model of diurnal cortisol patterns. Am J Physiol Endocrinol Metab. 2001;280:E450-61.
37. Klerman EB, Adler GK, Jin M, Maliszewski AM, Brown EN. A statistical model of diurnal variation in human growth hormone. Am J Physiol Endocrinol Metab. 2003;285:E1118-26.
38. Gupta S, Aslakson E, Gurbaxani BM, Vernon SD. Inclusion of the glucocorticoid receptor in a hypothalamic pituitary adrenal axis model reveals bistability. Theor Biol Med Model. 2007;4:8.
39. Roy A, Parker RS. Mixed meal modeling and disturbance rejection in type i diabetic patients. Proceedings of the 28th IEEE (EMBS Annual International Conference); 2006 Aug. 30; New York City.
40. Dalla Man C, Camilleri M, Cobelli C. A System model of oral glucose absorption: validation on gold standard data. IEEE Trans Biomed Eng. 2006;53:2472-8.
41. Derouich M, Boutayeb A. The effect of physical exercise on the dynamics of glucose and insulin. J Biomech. 2002;35:911.
42. Roy A, Parker RS. Dynamic modeling of exercise effects on plasma glucose and insulin levels. J Diabetes Sci Technol. 2007;1:338.
43. Dalla Man C, Rizza R, Cobelli C. Meal Simulation model of the glucose-insulin system. IEEE Trans Biomed Eng. 2007;54:1740-8.
44. Marliss EB, Murray FT, Stokes EF, Zinman B, Nakhooda AF, Denoga A, Leibel BS, Albisser AM. Normalization of glycemia in diabetics during meals with insulin and glucagon delivery by the artificial pancreas. Diabetes. 1977;26:663-72.
45. El-Khatib FH, Jiang J, Gerrity RG, Damiano ER. Adaptive closedloop control provides blood-glucose regulation using dual subcutaneous insulin and glucagon infusion in diabetic swine. J Diabetes Sci Technol. 2007;1:181.
46. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol. Ther. 2002;1:51-61.
47. Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21:1204-12.